Aarkstore Enterprise -------idera Pharmaceuticals, Inc. (idra) - Financial And Strategic Analysis R

Share:    

Idera Pharmaceuticals, Inc

Idera Pharmaceuticals, Inc. (Idera Pharmaceuticals) is a biotechnology company engaged in the discovery and development of drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer and respiratory diseases. It develops DNA and RNA based drug candidates that are targeted to Toll-Like Receptors (TLR) for treatment infectious diseases and for use as vaccine adjuvants. The company designed and formulated proprietary TLR agonists and antagonists to modulate immune responses. The company's lead drug candidate, IMO-2125, a TLR9 agonist is intended for the treatment of infectious diseases. It mainly operates in Europe and the US.

Idera Pharmaceuticals, Inc. Key Recent Developments

Apr 09, 2010: Idera Unveils TLR Antagonist Data In Preclinical Model Of Atherosclerosis

Apr 08, 2010: Idera Presents Data On Anti-Atherogenic Effects Of TLR Antagonist In Preclinical Model Of Atherosclerosis

Apr 07, 2010: Idera Announces Management Appointments And Promotion

Mar 10, 2010: Idera Pharmaceuticals Reports Net Income Of $3.9 Million In Q4 2009

Feb 15, 2010: Idera Releases Preclinical Hyperlipidemia Data On TLR Antagonist

This comprehensive SWOT analysis of Idera Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including,

- Business description A detailed description of the companys operations and business divisions.

- Corporate strategy Analysts summarization of the companys business strategy.

- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.

- Company history Progression of key events associated with the company.

- Major products and services A list of major products, services and brands of the company.

- Key competitors A list of key competitors to the company.

- Key employees A list of the key executives of the company.

- Executive biographies A brief summary of the executives employment history.

- Key operational heads A list of personnel heading key departments/functions.

- Important locations and subsidiaries A list and cont

For more information please contact :

http://www.aarkstore.com/reports/Idera-Pharmaceuticals-Inc-IDRA-Financial-and-Strategic-Analysis-Review-9891.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise

Contact: Neel

Email: press@aarkstore.com

URL: www.aarkstore.com

by:

POST COMMENT

Aarkstore Enterprise -------bio-bridge Science, Inc. (bges) - Financial And Strategic Analysis Revi Aarkstore Enterprise -------meldex International Plc (mdx) - Financial And Strategic Analysis Revie Aarkstore Enterprise -------neuro-hitech, Inc. (nhpi) - Financial And Strategic Analysis Review Finding Legitimate Reliable Wholesale Suppliers Driver Robot Crack Rapidshare Buy Wholesale Roses For Various Purposes Pakistan And Turkey Agree Strategic Partnership How to Achieve Great Trading Results Singorama 2.0 Rapidshare The Strategic CFO: Success Secrets of High Performing Finance Teams The Group of Shares or Currencies You Should Be Trading In - Ask These Questions! Where to Find Best Wholesale and Dropshippers? Dolat Ventures Inc. (OTCBB: DOLV) Trading at +50%